Search Results

Gynesonics®, Inc. is pleased to announce several executive appointments for the positions of Chief Marketing and Strategy Officer, Chief Human Resource Officer, and Vice President of Market Access and Reimbursement.

Gynesonics®, Inc. announced that with the support of the American College of Obstetrics and Gynecology, the American Medical Association has established a new Current Procedural Terminology Category I code, 58580, for transcervical uterine fibroid ablation with ultrasound guidance using radiofrequency.

Gynesonics®, Inc. a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, is pleased to announce that its Sonata® Procedure has been used to treat over 1,000 women in the United States and approximately 6,500 women globally.

Gynesonics®, Inc. a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, is please to announce that its Sonata® Procedure is now covered by UnitedHealthcare, effective August 1, 2023.

Gynesonics®, Inc. a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced that Skip Baldino was appointed in early March to the role of President and Chief Executive Officer of the company.

Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced that Robert Brown has joined the company as Chief Financial Officer, starting immediately.

Gynesonics®, a women’s healthcare company focused on the development of minimally invasive solutions for symptomatic uterine fibroids, announced today that David Pacitti, medical device executive and current President and Head of Siemens Healthineers for The Americas, has been appointed Chair of the company’s Board of Directors.